While type 2 diabetes and obesity are the primary conditions currently treated with blockbuster GLP-1 drugs, Novo Nordisk and Eli Lilly aim to enter additional markets.
Tag Archive for: GLP-1 drugs
Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.
Zealand Pharma on Thursday posted interim Phase Ib data for its investigational amylin analog petrelintide, touting strong weight reduction and a favorable tolerability profile.
The Tang Prize Foundation announced the 2024 Tang Prize in Biopharmaceutical Science recipients. The prestigious award has been jointly awarded to Joel F. Habener, Svetlana Mojsov, and Jens Juul Holst, for the discovery of GLP-1 (7-37) as an insulinotropic factor and the development of GLP-1 (7-37)-based anti-diabetic and anti-obesity drugs.
About one-third of U.S. employer health plans are offering coverage of GLP-1 drugs for both diabetes management and weight loss, up from last year, according to a survey of global employers released on Thursday by the International Foundation of Employee Benefit Plans.
M&A deal growth, the AI revolution, and the market surge of GLP-1 weight-loss medicines represent a trio of hot trends propelling the biopharmaceutical industry.
Seeking to carve out its own niche in the obesity space, Syntis Bio launched today to develop an oral weight-loss treatment that mimics the effects of gastric bypass surgery.
Monthly medication subscription to the retailer’s virtual healthcare platform, Whole Health Rx, starts at an introductory price of $219, and does not require insurance, the company said in a statement.
IRIS offers immersive insights reports and live dashboards designed to help the healthcare industry and other stakeholders anticipate and identify transformative market events, and how best to strategically navigate the fast-moving environment.
Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.